Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Roche: synergies provide boost despite vitamin deficiency

Roche's acquisition of Disetronic looks set to boost its presence in the diabetes market. But its enthusiasm will be tempered by news that the spin-off of its vitamin business will reap lower rewards than expected, while further funds must be set aside to settle price rigging claims. Even so, Roche and Disetronic will enjoy some valuable synergies.

Published By Datamonitor
12 Feb 2003
CommentWire
CommentWire

Pfizer: sale of a potential blockbuster

Pfizer's decision to keep Detrol and divest darifenacin to Novartis for $225 million is based purely on forecast projections. Detrol also has short-term blockbuster potential, while darifenacin may not offer significant advantages over Detrol or Johnson & Johnson's Ditropan, limiting its market penetration.

Published By Datamonitor
20 Mar 2003
CommentWire
CommentWire

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor
14 Apr 2003
CommentWire
CommentWire

Genentech: Avastin on track for 2004 launch

Genentech looks set to add Avastin to its growing number of successfully marketed innovative products, judging by the announcement of positive phase III clinical trial results in colorectal cancer patients. The results pave the way for Avastin to be launched in late 2004, making it the first angiogenesis inhibitor available for the treatment of colorectal cancer.

Published By Datamonitor
20 May 2003
CommentWire
CommentWire

Roche: Pegasys effective 4 years post-treatment

Recently presented efficacy data for Roche's [ROCZ.S] Hepatitis C drug Pegasys will increase physician confidence in the drug. This will provide the company with an additional and powerful marketing tool in the competition with Schering-Plough's [SGP] PEG-Intron, which has little in the way of similar data currently available.

Published By Datamonitor
09 Jul 2003
CommentWire
CommentWire

Eczema therapies: Fujisawa gets help as Novartis gains ground

The success of Novartis' [NVS] eczema cream in its first year of sales has caused Fujisawa [FJSPF.PK] to strengthen marketing arrangements for its own eczema drug in the key US market. Fujisawa's initial attempt to go it alone in the US has resulted in slow sales, but the struggle between Novartis and its Japanese rival is only just beginning.

Published By Datamonitor
14 Jul 2003
CommentWire
CommentWire

Novartis: bisphosphonate study should boost Zometa sales

A meta-analysis of bisphosphonate studies found that the drugs can lower skeletal morbidity in patients with metastatic disease. With Novartis' [NVS] Zometa recently gaining a sNDA for patients with bone metastases from advanced malignancies and this class of adjunct therapy becoming increasingly used, Zometa should be blockbuster by the end of 2003.

Published By Datamonitor
01 Sep 2003
CommentWire
CommentWire

Novartis: the COX-II story so far

Before the FDA asked for additional clinical data, Novartis' [NVS] Prexige was set to be the sixth brand to enter the COX-II market, which already contains Pfizer's [PFE] Celebrex (celecoxib) and Merck's [MRK] Vioxx (rofecoxib). As one of the few potential blockbusters Novartis has in its pipeline, the drug's approval is extremely important for its continuing financial health.

Published By Datamonitor
14 Oct 2003
CommentWire
CommentWire

Roche: poor results for NeoRecormon

Researchers have found that Roche's [ROCZ.S] anemia treatment NeoRecormon might worsen survival in head and neck cancer patients who undergo radiotherapy. Despite the poor findings, the study is unlikely to have any significant repercussions for NeoRecormon's rival erythropoietins, Amgen's [AMGN] Epogen and J&J's [JNJ] Procrit.

Published By Datamonitor
20 Oct 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.